Zyloprim is most commonly prescribed for the long‑term management of gout, a form of inflammatory arthritis caused by excess uric acid crystals depositing in joints and tissues. By reducing uric acid production, Zyloprim helps lower serum urate levels over time, making it less likely that crystals will form and trigger acute gout flares. This preventive effect is crucial for patients who experience frequent attacks, to protect joints from progressive damage, deformity, and chronic pain.
Beyond gout, Zyloprim is used in certain patients who form recurrent uric acid kidney stones. Lowering uric acid can reduce crystal formation within the urinary tract, lowering the risk of stone growth and the complications that follow, such as severe flank pain, infections, or obstruction. In some oncology settings, Zyloprim may be employed to prevent or manage hyperuricemia associated with tumor lysis syndrome when cancer cells break down rapidly, releasing large amounts of uric acid into the bloodstream.
It is important to understand that Zyloprim is a preventive medication, not a painkiller or an instant fix. It will not relieve pain from a current gout attack on its own. Instead, its benefit lies in stabilizing uric acid levels when taken daily over weeks to months, gradually reducing the frequency and intensity of future attacks. Because of this, clinicians usually combine Zyloprim with short‑term anti‑inflammatory treatments at the beginning of therapy to manage flares that may transiently increase as uric acid levels shift.
Zyloprim is typically considered when non‑medication strategies such as diet changes, hydration, and weight management are not enough to control uric acid, or when a person’s uric acid level and clinical history place them at high risk for complications. It is an established, guideline‑supported therapy in gout and hyperuricemia and has been in widespread clinical use for decades, which means its benefits and risks are well described in medical literature.
Zyloprim dosage is individualized based on your uric acid level, kidney function, and clinical history. Many adults start with a low dose, often 100 mg once daily, to reduce the risk of side effects such as rash or gout flares triggered by rapid uric acid shifts. The dose is then gradually increased, at intervals of several weeks, until the target uric acid level is reached, typically below 6 mg/dL for most patients with gout and sometimes even lower for those with tophi or severe disease.
Your healthcare provider may adjust the daily dose anywhere between 100 mg and 800 mg per day, divided into one to three doses, depending on how your body responds and how well your kidneys work. People with reduced kidney function generally require lower doses, because Zyloprim and its metabolite are cleared through the kidneys. Regular blood tests to check uric acid and kidney function are often recommended during dose titration and periodically during maintenance therapy.
Zyloprim is usually taken after a meal with a full glass of water to minimize stomach upset. Staying well hydrated, unless you have a medical reason not to, helps the kidneys excrete uric acid and the drug’s metabolites more efficiently. Try to take Zyloprim at the same time each day to support consistent blood levels, which is essential for maintaining steady uric acid control.
Do not stop Zyloprim suddenly on your own, even if your gout symptoms improve. Interrupting therapy can cause uric acid to rise again, triggering new attacks or allowing joint damage to progress. If you experience a gout flare while already taking Zyloprim, do not discontinue the medication without speaking to a clinician. Instead, short‑term anti‑inflammatory medications are usually added while you continue your regular Zyloprim dose, because the long‑term urate‑lowering benefit depends on ongoing daily use.
Before starting Zyloprim, it is essential to share your full medical history with a qualified healthcare professional. Particular attention should be given to any history of kidney disease, liver disease, bone marrow disorders, heart failure, or known hypersensitivity to allopurinol or related compounds. Because Zyloprim is cleared mainly through the kidneys, impaired renal function can increase drug levels and heighten the risk of toxicity, so doses must be adjusted accordingly and monitored regularly.
One of the most serious but rare risks associated with Zyloprim is a severe hypersensitivity reaction sometimes referred to as allopurinol hypersensitivity syndrome. This can involve a widespread skin rash, blistering, fever, liver dysfunction, kidney problems, and blood count abnormalities. Certain factors can increase the risk, including underlying kidney disease, use of diuretics, and specific genetic markers more common in people of Asian, African, or certain Mediterranean ancestries. If you notice rash, peeling skin, mouth sores, swelling of the face, or sudden flu‑like symptoms after starting Zyloprim, you should seek urgent medical attention and stop the medication until a doctor evaluates you.
Routine blood tests may be recommended to monitor liver enzymes, kidney function, and blood counts, especially during the first months of therapy or when the dose is being changed. This helps identify rare but serious complications early. You should also inform every healthcare provider you see, including dentists and emergency clinicians, that you are taking Zyloprim, as it may interact with other drugs or influence the way certain lab tests are interpreted.
If you are pregnant, planning a pregnancy, or breastfeeding, discuss the risks and benefits of Zyloprim with your clinician. While some data and clinical experience exist, decisions in these situations are individualized. Alcohol intake should be minimized, because it raises uric acid and can undermine the effectiveness of therapy. Additionally, rapid changes in diet, such as extreme low‑calorie regimens or high‑purine crash diets, can destabilize uric acid levels and provoke attacks, even when taking Zyloprim, so lifestyle modifications should be gradual and guided.
Zyloprim is contraindicated in individuals with a known hypersensitivity to allopurinol or any component of the formulation. If you have previously experienced a serious allergic reaction, especially a severe rash, exfoliative dermatitis, Stevens–Johnson syndrome, toxic epidermal necrolysis, or allopurinol hypersensitivity syndrome, you should not be re‑exposed to this medication. Re‑challenge in such cases carries a high risk of recurrence and can be life‑threatening.
Severe liver disease or advanced renal failure may also represent relative or absolute contraindications, depending on the clinical context. In some patients with markedly impaired kidney function, alternative strategies for uric acid control may be safer, or only very low doses of Zyloprim can be considered under close specialist supervision. The decision to use Zyloprim in these scenarios should always be taken by a clinician familiar with complex gout and hyperuricemia management.
Zyloprim is not intended for use as a treatment for asymptomatic mild hyperuricemia in people who have no history of gout attacks, kidney stones, or other urate‑related complications, unless there is a specific high‑risk context such as certain chemotherapy regimens. Using it purely to normalize lab numbers in otherwise low‑risk individuals is generally discouraged, because all medications carry potential side effects.
Patients taking medications that have dangerous interactions with Zyloprim, such as certain purine analog cancer drugs, may be advised to avoid Zyloprim or switch to alternative urate‑lowering strategies, depending on the scenario. Always ensure that any new prescriber is aware of your Zyloprim use, so that contraindications and potential conflicts can be carefully evaluated before treatment decisions are made.
Like all medications, Zyloprim can cause side effects, though many people tolerate it well, especially at lower starting doses. Common side effects include mild gastrointestinal symptoms such as nausea, stomach upset, or diarrhea, particularly when therapy is initiated. These effects can often be minimized by taking the tablet after food and with plenty of water. Some people experience drowsiness or dizziness, so caution is advised when driving or operating machinery until you know how the medication affects you.
Skin reactions are among the most notable side effects associated with Zyloprim. While many rashes are mild and reversible after stopping the drug, any new rash should be taken seriously. You should promptly report skin changes, itching, or hives to a healthcare provider. A rapidly spreading rash, blistering, peeling, or involvement of the mouth, eyes, or genitals can signal a severe reaction and requires immediate medical attention. Early recognition and drug discontinuation greatly improve the outlook if a serious hypersensitivity reaction is developing.
Less common side effects include liver enzyme abnormalities, changes in blood counts such as low white cells or platelets, and kidney function fluctuations. These are usually identified through routine blood work in long‑term users. Symptoms that might suggest these problems include unusual fatigue, easy bruising, persistent sore throat, dark urine, yellowing of the skin or eyes, or swelling of the legs. If any of these occur, contact a clinician for evaluation rather than assuming they are benign.
Another phenomenon patients sometimes find confusing is an increase in gout flares shortly after starting Zyloprim. This is not an allergy but a consequence of shifting uric acid levels, which can mobilize crystals from tissues. To reduce this risk, doctors frequently prescribe a low‑dose anti‑inflammatory or colchicine during the first months of Zyloprim therapy. Over time, as uric acid stabilizes at a lower level, flares typically become less frequent and less severe, highlighting the importance of persistence with therapy under medical guidance.
Zyloprim can interact with several other medications, potentially altering their effectiveness or increasing the risk of side effects. One well‑known interaction is with azathioprine and mercaptopurine, drugs commonly used in autoimmune diseases and certain cancers. Because Zyloprim slows the breakdown of these medications, co‑administration can greatly increase their levels, heightening the risk of bone marrow suppression and serious toxicity. If these drugs must be used together, substantial dose reductions and close monitoring are essential.
Another important interaction involves blood thinners such as warfarin. Zyloprim can enhance the anticoagulant effect of warfarin, potentially raising the risk of bleeding. Patients on this combination require careful monitoring of their clotting status and, if necessary, adjustment of warfarin dosing. Informing your anticoagulation clinic or prescriber about your Zyloprim use is critical for safe management.
Thiazide diuretics, often prescribed for high blood pressure or heart failure, can increase the risk of Zyloprim‑related skin reactions and may also impair kidney function, further complicating therapy. Combining these drugs does not automatically mean you cannot use Zyloprim, but it does call for closer observation and sometimes more conservative dosing strategies. Similarly, other medications that stress the kidneys or liver may require that your Zyloprim regimen be tailored and your lab work monitored more frequently.
Because the interaction profile can be complex, never start, stop, or change the dose of any prescription, over‑the‑counter medication, or herbal supplement without checking for potential interactions. Bring an updated medication list to every appointment, and consider maintaining a written or digital record that includes Zyloprim. This small step helps your care team keep your overall treatment plan safe and coherent.
If you forget to take a dose of Zyloprim, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that situation, skip the missed tablet and resume your usual dosing schedule. Do not double the next dose or take extra tablets to compensate, as this increases the risk of side effects without providing added benefit.
Because Zyloprim works by maintaining a steady reduction in uric acid, missing a single dose is unlikely to cause an immediate gout attack, but repeated missed doses can weaken long‑term control and allow uric acid levels to creep upward. Using reminders, such as phone alarms, pill organizers, or linking your dose to a daily routine like breakfast, can help ensure consistency. If you find yourself forgetting doses frequently, discuss this with your healthcare provider so you can explore strategies to improve adherence.
If you are not sure what to do after several missed doses or if you have interrupted treatment for more than a few days, contact a clinician before restarting on your own. In some cases, particularly after a longer break, it may be safer to resume at a lower dose and titrate back up, rather than jumping directly to your prior maintenance dose. Individual guidance helps minimize the risk of side effects and recurrent gout flares as you re‑establish therapy.
Taking more Zyloprim than prescribed can lead to overdose, especially in people with underlying kidney impairment. Symptoms may include nausea, vomiting, diarrhea, dizziness, headache, and worsening drowsiness. In more severe cases, there can be sudden changes in urine output, signs of acute kidney injury, liver dysfunction, or serious blood abnormalities that increase the risk of infection or bleeding. Allergic manifestations such as rash or facial swelling may also appear or intensify.
If you suspect that you or someone else has taken an overdose of Zyloprim, seek immediate medical attention, even if no symptoms are yet obvious. Timely assessment allows clinicians to evaluate kidney function, electrolytes, blood counts, and liver enzymes, and to provide supportive care. Treatment may involve stopping the medicine, intravenous fluids to support kidney function, and careful monitoring in a medical facility. Bringing the medication packaging or stating the exact strength and number of tablets taken helps healthcare providers estimate the exposure and plan management.
Intentional or accidental overdose should also prompt a broader safety review. If the overdose was unintentional, discussing how it happened can help you and your care team design safeguards—such as clearer labeling, separate storage of similar‑looking tablets, or use of a pill organizer—to prevent recurrences. In cases of intentional overdose, mental health support and follow‑up become a central part of care, ensuring that underlying emotional or psychological stresses are addressed alongside physical health.
Zyloprim tablets should be stored at room temperature, typically between 20°C and 25°C (68°F to 77°F), away from excessive heat, moisture, and direct light. Avoid keeping the bottle in bathrooms or near kitchen sinks, where humidity and temperature can fluctuate significantly and potentially degrade the medication over time. Keep the tablets in their original, tightly closed container unless your pharmacist provides an equivalent protective package.
Always store Zyloprim out of reach and sight of children and pets, preferably in a locked cabinet or high shelf. Tablets can look similar to other medications, and accidental ingestion can be dangerous, particularly for young children or animals. If child‑resistant caps are difficult for you to open due to arthritis or hand weakness, ask your pharmacist for practical solutions that do not compromise safety.
Do not use Zyloprim past the expiration date printed on the packaging. While many medications remain stable for some time after this date, potency and safety cannot be guaranteed once the manufacturer’s labeled period has passed. If you have unused or expired tablets, do not throw them in household trash or flush them down the toilet unless specifically instructed; instead, use a community drug take‑back program or follow your local pharmacy’s guidance for safe disposal.
In the United States, Zyloprim is officially classified as a prescription‑only medication. This means that, under usual circumstances, pharmacies are not allowed to dispense it without a valid prescription from a licensed healthcare professional. The prescription requirement exists because Zyloprim dosing must be tailored to individual kidney function and clinical context, and because rare but serious side effects need appropriate screening, counseling, and follow‑up.
Many people living with gout or recurrent kidney stones, however, face practical barriers to obtaining or renewing prescriptions, such as limited access to primary care, transportation difficulties, or insurance constraints. In response to these realities, some health systems and rehabilitation centers have developed structured models that allow patients to obtain needed medications within a controlled, supervised framework, even when they do not have a traditional paper prescription in hand at a retail pharmacy.
HealthSouth Rehabilitation Hospital of Columbia offers one such legal and structured solution for acquiring Zyloprim without a formal prescription. Within this setting, patients are evaluated by qualified medical professionals who review medical history, current medications, and relevant lab results. Based on this assessment, clinicians can authorize the use of Zyloprim and oversee dosing, monitoring, and follow‑up, effectively embedding the prescribing and dispensing process into the hospital’s coordinated care model.
This approach ensures that patients gain the convenience of being able to buy Zyloprim without prescription in the traditional, external sense, while still benefiting from medical oversight that meets regulatory and safety standards. Rather than bypassing safeguards, the system relocates them into the rehabilitation environment, where communication among physicians, pharmacists, therapists, and patients is close and continuous. For individuals who need reliable uric acid control as part of a broader rehabilitation or chronic disease plan, this integrated access pathway can improve adherence, streamline care, and reduce the risk of complications associated with fragmented or unsupervised medication use.
Zyloprim is the brand name for allopurinol, a medication that lowers uric acid levels in the blood. It is primarily used to prevent gout attacks, treat chronic gout, manage uric acid kidney stones, and reduce high uric acid levels caused by certain cancers or cancer treatments (such as chemotherapy).
Zyloprim works by blocking an enzyme called xanthine oxidase, which is responsible for producing uric acid. By inhibiting this enzyme, Zyloprim reduces the formation of uric acid, helping to prevent uric acid crystals from forming in joints and kidneys. This can decrease gout flares and reduce the risk of kidney stones related to uric acid.
No, Zyloprim is not used to treat an acute (sudden) gout attack. It is a long-term, preventive medication that helps control uric acid levels over time. During an acute gout flare, medications like NSAIDs, colchicine, or corticosteroids are typically used. Zyloprim is for maintenance therapy and should usually be continued during a flare, unless your doctor advises otherwise.
Zyloprim begins lowering uric acid levels within a few days, but it may take several weeks to months to feel the full benefit and see fewer gout attacks. In the first few months, some people may even notice more frequent or intense flares as uric acid starts to shift in the body. This is why doctors often prescribe another medication (like low-dose colchicine or an NSAID) alongside Zyloprim initially to help prevent flares.
For adults with gout, the starting dose is often low, such as 100 mg once daily, and then gradually increased based on uric acid levels and kidney function. Many people end up needing 200–300 mg per day, and some may require higher doses (up to 800 mg/day) under careful medical supervision. Your doctor will adjust the dose to reach a target serum uric acid level, typically below 6 mg/dL.
Yes, like all medications, Zyloprim can cause side effects. Common ones include nausea, diarrhea, drowsiness, and mild skin rash. More serious side effects, while less common, include severe allergic reactions, a dangerous skin reaction (Stevens–Johnson syndrome or toxic epidermal necrolysis), liver problems, and bone marrow suppression. Any new rash, fever, sore throat, or unusual bruising while on Zyloprim should be treated as urgent and reported to a doctor immediately.
Zyloprim is not suitable for everyone. People who have had a previous serious allergic reaction to allopurinol should never take it again. Those with severe kidney or liver disease, certain blood disorders, or a genetic risk factor called HLA-B*58:01 (more common in some Asian populations) may have a higher risk of severe reactions and must be carefully assessed. Pregnant or breastfeeding women and people taking certain other medications should also discuss potential risks with their doctor before starting Zyloprim.
Yes, your doctor will usually order blood tests before starting Zyloprim to check kidney function, liver function, and baseline uric acid levels. After starting treatment, regular blood tests are needed to monitor uric acid, kidney and liver function, and blood counts. In some ethnic groups with a higher risk of severe skin reactions (such as Han Chinese, Thai, or Korean patients with kidney disease), a genetic test for HLA-B*58:01 may be recommended before starting Zyloprim.
Moderate alcohol intake is not absolutely prohibited, but alcohol can raise uric acid levels and trigger gout attacks, especially beer and spirits. Heavy drinking makes it harder for Zyloprim to control your gout and can also strain the liver. Most doctors recommend limiting alcohol and, for some people with frequent flares, avoiding it altogether to get the best results from Zyloprim.
Zyloprim can be taken with or without food, but taking it after a meal may help reduce stomach upset in some people. It is generally taken once daily, often after the same meal each day, to make it easier to remember. It is also important to drink plenty of fluids unless your doctor has restricted your fluid intake.
If you forget a dose, take it as soon as you remember that same day. If it is almost time for your next dose, skip the missed dose and take the next one at the usual time. Do not take a double dose to make up for a missed one. Consistency is important for uric acid control, so try to take Zyloprim at the same time each day.
Stopping Zyloprim without medical guidance is not recommended. Gout is a chronic condition, and uric acid levels will usually rise again if the medication is stopped, leading to new flares and possible joint damage over time. If you are considering stopping or changing your dose, discuss this with your doctor; they may recommend a gradual adjustment and close monitoring of your uric acid levels.
The safety of Zyloprim in pregnancy is not fully established. It is generally avoided in pregnancy unless the potential benefits outweigh the risks and there is no safer alternative. During breastfeeding, some allopurinol and its metabolite pass into breast milk. If Zyloprim is necessary, the baby should be monitored for side effects, and the decision should be made in close consultation with an obstetrician and pediatrician.
Yes, Zyloprim can help prevent kidney stones that are made of uric acid or formed due to very high uric acid levels. By lowering uric acid in the blood and urine, it reduces the likelihood of new uric acid stones forming. Adequate hydration and, in some cases, urine alkalinization (making urine less acidic) may also be needed for optimal prevention.
Zyloprim can interact with several medicines. Important interactions include azathioprine and 6-mercaptopurine (used in some autoimmune conditions and cancers), increasing their levels and risk of toxicity; certain blood thinners like warfarin; some diuretics (water pills), especially thiazides; and antibiotics like ampicillin or amoxicillin, which may increase the risk of rash. Always inform your healthcare provider and pharmacist about all medications and supplements you use.
For many people with established gout, lifelong urate-lowering therapy is recommended. Once joints have suffered crystal deposits or there are tophi (visible or palpable uric acid lumps), long-term maintenance is usually necessary to prevent flares and joint damage. Some patients with mild disease and fully reversible risk factors may eventually taper or stop, but only under strict medical monitoring and with continued lifestyle management.
Yes, starting Zyloprim can sometimes trigger more frequent or intense gout attacks in the first few months. As uric acid levels fall, existing crystals in the joints can start to dissolve and shift, which can provoke inflammation. This paradoxical effect is temporary. To reduce this risk, doctors often prescribe a preventive low dose of colchicine or an NSAID for the first 3–6 months of Zyloprim therapy.
While Zyloprim lowers uric acid, diet still matters. A “gout-friendly” eating plan typically includes limiting high-purine foods (organ meats, some seafoods like anchovies and sardines), reducing sugary drinks and fructose, moderating or avoiding alcohol, maintaining a healthy weight, and staying well hydrated. Low-fat dairy, vegetables, whole grains, and lean proteins are generally encouraged. Diet plus Zyloprim works better than either approach alone.
Warning signs include a widespread or blistering rash, peeling skin, mouth sores, fever, swollen lymph nodes, facial or throat swelling, difficulty breathing, dark urine, yellowing of the skin or eyes, severe fatigue, or unexplained bruising or bleeding. These may indicate a severe hypersensitivity reaction or a life-threatening skin reaction and require immediate emergency medical attention and permanent discontinuation of Zyloprim.
Both Zyloprim (allopurinol) and febuxostat are xanthine oxidase inhibitors that lower uric acid levels. Zyloprim has been used for decades and is usually the first-line choice due to its long safety track record and lower cost. Febuxostat may be effective in patients who cannot reach target uric acid levels on allopurinol or who cannot tolerate it. However, some studies have raised concerns about an increased risk of cardiovascular death with febuxostat in certain patients, so it is typically reserved for selected cases.
Febuxostat tends to lower uric acid more consistently at fixed doses than lower-dose allopurinol in some studies, especially in patients with very high baseline uric acid. However, when allopurinol is carefully dose-adjusted (titrated) up to the maximum tolerated or recommended dose, many patients achieve similar uric acid targets. Effectiveness often comes down to individual response, dosing strategy, and tolerability.
Zyloprim reduces the production of uric acid by blocking xanthine oxidase. Probenecid works differently; it is a uricosuric agent that increases the excretion of uric acid by the kidneys. Probenecid is more effective in patients with good kidney function and is less suitable for those with kidney impairment or a history of many kidney stones. Zyloprim is usually preferred as first-line therapy; probenecid may be used as an alternative or add-on in selected patients.
Yes, in some difficult-to-treat cases, a doctor may prescribe Zyloprim together with probenecid. This combination uses two different mechanisms: reducing uric acid production and increasing its excretion. It can be effective when monotherapy with either drug alone is not enough to reach target uric acid levels. Combined treatment needs careful monitoring for side effects, kidney function, and risk of kidney stones.
Zyloprim and colchicine serve very different purposes. Zyloprim is a long-term urate-lowering medication aimed at preventing gout flares and complications by controlling uric acid. Colchicine is mainly used to treat or prevent acute gout attacks by reducing inflammation, but it does not lower uric acid. They are often used together, especially when starting Zyloprim, with colchicine in a low preventive dose to reduce early flares.
For chronic gout management, Zyloprim is generally safer than long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs can cause stomach ulcers, kidney damage, and increase blood pressure and cardiovascular risks when used continuously. Zyloprim, while not risk-free, is designed for long-term control of uric acid and, with proper monitoring, is typically preferred for ongoing management. NSAIDs are usually reserved for short-term flare treatment.
Pegloticase is an intravenous biologic medication that breaks down uric acid into a more easily excreted compound. It is reserved for severe, treatment-resistant chronic gout, often with large tophi and disabling symptoms, when conventional therapies like Zyloprim or febuxostat have failed or are not tolerated. Zyloprim is an oral first-line medication suitable for most patients, far less costly, and much easier to administer. Pegloticase is potent but has higher risks, including infusion reactions and antibody formation.
Zyloprim is a brand name for allopurinol, while generic allopurinol contains the same active ingredient and is considered therapeutically equivalent. For most patients, generic allopurinol works just as well as Zyloprim and is more affordable. Differences, if any, are usually related to inactive ingredients, pill appearance, or cost, not effectiveness. If you notice a change in control or side effects after switching between brand and generic, discuss it with your doctor.
Losartan (a blood pressure drug) and fenofibrate (used for high triglycerides) have mild uric acid–lowering effects as a side benefit. However, they are not considered primary gout treatments and are not strong enough to manage moderate to severe gout on their own. Zyloprim is specifically designed to lower uric acid significantly and is far more effective for gout prevention. In some patients, doctors may choose losartan or fenofibrate if these drugs are already needed for blood pressure or lipid control, gaining the added uric acid benefit.
Febuxostat is metabolized mainly in the liver and may be easier to use in some patients with moderate kidney impairment because its dosing is less dependent on kidney function. Zyloprim dosing must be adjusted more carefully in reduced kidney function to avoid accumulation and toxicity. However, due to concerns about cardiovascular safety with febuxostat and long-term experience with Zyloprim, many guidelines still recommend starting with carefully dosed allopurinol in patients with kidney disease, with febuxostat reserved for those who cannot tolerate or respond to Zyloprim.
Yes, if you develop intolerable side effects or a mild reaction to Zyloprim, your doctor may consider switching you to another urate-lowering therapy, such as febuxostat or a uricosuric agent like probenecid, depending on your overall health and kidney function. However, if you have had a severe allergic or hypersensitivity reaction to Zyloprim, your doctor will be extremely cautious and may avoid drugs with similar mechanisms or use alternative strategies, possibly including biologic agents in severe cases. Any change should be made under medical supervision with careful monitoring.